The green light for the pre-filled, single-use pen version of Tezspire (tezepelumab) comes just four months after the TSLP inhibitor became the first biologic therapy for severe asthma to be cleared in the EU for use in all patients, and not restricted to those with forms of the disease tied to specific characteristics such as high levels of eosinophils.
AZ’s head of biopharma R&D Mene Pangalos said the new device would help support the use of Tezspire to treat “a broad population of severe asthma patients.” It is estimated that there are 2.5 million patients worldwide with severe asthma who are uncontrolled, without any phenotypic and biomarker limitation.
